Format

Send to

Choose Destination
J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22.

Scientific Advances in Lung Cancer 2015.

Author information

1
Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas.
2
San Luigi Hospital, University of Turin, Orbassano, Italy.
3
Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado.
4
Division of Medical Oncology, The Ohio State University, Columbus, Ohio.
5
Department of Radiation Oncology, Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.
6
Shanghai Respiratory Research Institute, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, People's Republic of China.
7
Erasmus Medical Center, University Medical Center Rotterdam, Department of Public Health, Rotterdam, The Netherlands.
8
Fiona Stanley Hospital, Murdoch, Western Australia and University of Western Australia, Perth, Western Australia, Australia.
9
Department of Laboratory Medicine and Pathobiology, University Health Network and Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
10
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York.
11
Department of Thoracic Surgery, Hospital Universitari Mutua Terrassa, University of Barcelona, Barcelona, Spain; Centros de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Lung Cancer Group, Terrassa, Barcelona, Spain.
12
Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan.
13
Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem (Antwerp), Belgium.
14
Division of Thoracic Surgery University of Toronto, Toronto, Canada.
15
Department of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
16
Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
17
Department of Radiation Oncology at Icahn School of Medicine at Mount Sinai, New York, New York.
18
Department of Oncology, HFR Fribourg, Fribourg, Switzerland.
19
Department of Oncology, University of Lausanne, Lausanne, Switzerland.
20
Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California.
21
Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
22
Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
23
Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, People's Republic of China.
24
Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California.
25
Department of Medicine I, Medical University of Vienna, Vienna, Austria.
26
Larrey Hospital, Paul Sabatier University, Toulouse, France.
27
Johns Hopkins Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland.
28
Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut.
29
Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut.
30
Fred Hutchinson Cancer Research Center, Public Health Sciences Division Seattle, Washington.
31
International Association for the Study of Lung Cancer, Aurora, Colorado.
32
Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, Sacramento, California.
33
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins, Johns Hopkins, Baltimore, Maryland.
34
Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado. Electronic address: Fred.Hirsch@ucdenver.edu.
35
Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, New York.

Abstract

Lung cancer continues to be a major global health problem; the disease is diagnosed in more than 1.6 million new patients each year. However, significant progress is underway in both the prevention and treatment of lung cancer. Lung cancer therapy has now emerged as a "role model" for precision cancer medicine, with several important therapeutic breakthroughs occurring during 2015. These advances have occurred primarily in the immunotherapy field and in treatments directed against tumors harboring specific oncogenic drivers. Our knowledge about molecular mechanisms for oncogene-driven tumors and about resistance to targeted therapies has increased quickly over the past year. As a result, several regulatory approvals of new agents that significantly improve survival and quality of life for patients with lung cancer who have advanced disease have occurred. The International Association for the Study of Lung Cancer has gathered experts in different areas of lung cancer research and management to summarize the most significant scientific advancements related to prevention and therapy of lung cancer during the past year.

KEYWORDS:

Adjuvant chemotherapy; Biomarkers; Cancer prevention; Gene mutations; Immunotherapy; Lung cancer; Master protocols; Pathology; Radiotherapy; Screening; Smoking cessation; Staging; Surgery; Targeted therapy; Value of therapy

PMID:
27013409
DOI:
10.1016/j.jtho.2016.03.012
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center